Beckley Psytech - About the company
Beckley Psytech is a series B company based in Oxford (United Kingdom), founded in 2019 by Cosmo Feilding Mellen and Amanda Feilding. It operates as a Developer of rapid-acting psychedelic medicines for mental health disorders. Beckley Psytech has raised $153M in funding from investors like Bain Capital, ATAI and Noetic Psychedelic Fund, with a current valuation of £*****. The company has 89 active competitors, including 20 funded and 24 that have exited. Its top competitors include companies like Alto Neuroscience, Enveda and Vanda Pharmaceuticals.
Company Details
Developer of rapid-acting psychedelic medicines for mental health disorders. The firm targets neurological and psychiatric conditions with short-duration psychedelics, aiming for scalable treatments that allow quick patient discharge, often within two hours.
- Website
- beckleypsytech.com
- Social
- Registered Address
- SUITE 11,216 MAIN ROAD,BIGGIN HILL,KENT,TN16 3BD
Key Metrics
Founded Year
2019
Location
Oxford, United Kingdom
Stage
Series B
Total Funding
$153M in 4 rounds
Latest Funding Round
Post Money Valuation
£***** as on Aug 10, 2021
Investors
Ranked
7th among 89 active competitors
Employee Count
65 as on Oct 11, 2025
Investment & Acquisitions
Similar Companies
Legal entities associated with Beckley Psytech
Beckley Psytech is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
PSYTECH LIMITED CIN: 2365040 , United Kingdom, Active | Mar 22, 1989 | - | 7 (As on Mar 31, 2025) | |
BECKLEY PSYTECH US CIN: 872996953 , United States, Active | Dec 31, 1999 | - | 1 (As on Dec 31, 2022) | - |
Beckley Psytech Limited CIN: 11496099 , United Kingdom, Active | Aug 01, 2018 | - | 35 (As on Dec 31, 2024) |
Sign up to download Beckley Psytech's company profile
Beckley Psytech's funding and investors
Beckley Psytech has raised a total funding of $153M over 4 rounds. Its first funding round was on Jul 01, 2020. Its latest funding round was a Series B round on Jan 04, 2024 for $*****. 1 investor participated in its latest round. Beckley Psytech has 26 institutional investors and 2 angel investors.
Here is the list of recent funding rounds of Beckley Psytech:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 04, 2024 | 4685143 | Series B | 1114171 | 4597650 | 9099531 | 8411684 |
Aug 15, 2021 | 8292176 | Series B | 9814850 | 4580161 | 8993395 | |
Dec 20, 2020 | 7140108 | Series B | 7089208 | 8746906 |
Access funding benchmarks and valuations. Sign up today!View details of Beckley Psytech's funding rounds and investors
Beckley Psytech's founders and board of directors
Founder? Claim ProfileThe founders of Beckley Psytech are Cosmo Feilding Mellen and Amanda Feilding. Cosmo Feilding Mellen is the CEO of Beckley Psytech.
Here are the details of Beckley Psytech's key team members:
- Cosmo Feilding Mellen: Co-Founder & CEO of Beckley Psytech. They are also an angel investor in 1 startup.Contact Info: 1 email address
- Amanda Feilding: Co-Founder of Beckley Psytech.
Beckley Psytech's Board of Directors
Beckley Psytech's board has 4 active members. Srinivas Rao, Gerd Georg Kochendoerfer, Christopher Ryan Barrett and Robert Hershberg are independent board members.Here is the list of Beckley Psytech's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
vcelkh{ | Team | - | Past | 7y 3m |
Independent board member | - | Current | 2y 3m | |
o{stldu | Independent board member | - | Current | 8y 4m |
fslezyj | Independent board member | - | Current | 9y 8m |
ybmkbcn | Independent board member | - | Current | 7y 5m |
wfsejrr | Independent board member | - | Past | 1y 9m |
qxhzosc | Independent board member | - | Past | 3y 9m |
{gritkt | Independent board member | - | Past | 5y 7m |
mtuxnqg | Independent board member | - | Past | 5y 9m |
View details of Beckley Psytech's Founder profiles and Board Members
Beckley Psytech's employee count trend
Beckley Psytech has 65 employees as of Oct 25. Here is Beckley Psytech's employee count trend over the years:
Uncover Beckley Psytech's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Beckley Psytech's Competitors and alternates
Top competitors of Beckley Psytech include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Here is the list of Top 10 competitors of Beckley Psytech, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Alto Neuroscience 2019, San Francisco (United States), Public | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | $145M | 68/100 | |
2nd |  Enveda 2019, Boulder (United States), Series D | AI-based platform to decipher the chemistry of nature and develop new medicines | $517M | 63/100 | |
3rd |  Vanda Pharmaceuticals 2003, Washington, DC (United States), Public | Developer of pharmaceutical products for treating CNS disorders | $33.5M | 62/100 | |
4th |  Reunion Neuroscience 2022, Toronto (Canada), Acquired | Developer of therapeutics for mental health conditions | $120M | 62/100 | |
5th |  Seaport Therapeutics 2020, Boston (United States), Public | Developer of therapeutics to treat neuropsychiatric disorders | $325M | 60/100 | |
6th | Supernus Pharmaceuticals 2005, Rockville (United States), Public | Innovating CNS treatments, improving lives through neurological and psychiatric solutions | - | 59/100 | |
7th |  Beckley Psytech 2019, Oxford (United Kingdom), Series B | Developer of rapid-acting psychedelic medicines for mental health disorders | $153M | 64/100 | |
8th | Reviva Pharmaceuticals 2006, San Jose (United States), Public | Develops therapeutic drugs for treatment of central nervous system | $49.1M | 53/100 | |
9th | Neurovance 2011, Cambridge (United States), Acquired | Drug to modulate neurochemicals to treat Attention Deficit Hyperactivity Disorder . | $53M | 53/100 | |
10th | HMNC Brain Health 2010, Munich (Germany), Series B | Developer of targeted therapies for depression and other neuropsychiatric disorders | $41.5M | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Beckley Psytech's competitors? Click here to see the top ones
Beckley Psytech's Investments and acquisitions
Beckley Psytech has acquired Eleusis. Beckley Psytech has not made any investments as of now.Reports related to Beckley Psytech
Here is the latest report on Beckley Psytech's geography:
News related to Beckley Psytech
Filter this listMedia has covered Beckley Psytech for a total of 7 events in the last 1 year, 4 of them have been about company updates.
•
Atai Life Sciences and Beckley Psytech Complete Merger, Forming AtaiBeckleyGlobeNewswire•Nov 05, 2025•atai Life Sciences, Beckley Psytech
•
•
Atai, Beckley psychedelic advances to pivotal TRD trial after positive Phase IIa resultsclinicaltrialsarena.com•Sep 24, 2025•atai Life Sciences, Beckley Psytech
•
•
•
•
•
•
•
Beckley Psytech completes subjects’ enrolment for Phase IIb trial of TRD therapyclinicaltrialsarena.com•Mar 06, 2025•Beckley Psytech
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Beckley Psytech
Explore our recently published companies
- Yug Global - Mumbai based, 2007 founded, Unfunded company
- Bateman Engineering - Aurora based, 1999 founded, Acquired company
- Nxtinfratrust.com - Unfunded company
- Greenhorn Wellness - Bengaluru based, 2020 founded, Unfunded company
- Infiligence - Pleasanton based, 2024 founded, Unfunded company
- Gmfoods.co.in - India based, Unfunded company
